Ramipryl z amlodypiną – klasycznie, wciąż skutecznie Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2017
Słowa kluczowe:
nadciśnienie tętnicze, ramipryl, amlodypina, preparat skojarzony
##plugins.themes.bootstrap3.article.main##
Abstrakt
Nadciśnienie tętnicze jest zjawiskiem powszechnym. Pomimo coraz większej świadomości społecznej wciąż jednak u zbyt małego odsetka osób trwale uzyskujemy prawidłową kontrolę ciśnienia tętniczego. Większość pacjentów z nadciśnieniem tętniczym wymaga przynajmniej 2 leków hipotensyjnych. Aktualne wytyczne zachęcają, aby stosować gotowe skojarzenia lekowe. Jednocześnie odchodzi się obecnie od pojęcia efektu klasy, a decydując o schemacie farmakoterapii, coraz częściej analizujemy właściwości konkretnych cząsteczek. W niniejszym artykule przedstawiono omówienie najważniejszych właściwości ramiprylu i amlodypiny oraz dotyczących ich badań. Chociaż leki te od lat są dostępne na rynku, ich połączenie wciąż stanowi atrakcyjną i jednocześnie nie w pełni wykorzystywaną w praktyce opcję terapeutyczną.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Wełnicki , M., Chmielewski , M., Janiszewski , M., & Mamcarz , A. (2017). Ramipryl z amlodypiną – klasycznie, wciąż skutecznie . Medycyna Faktów , 10(4(37), 336-343. https://doi.org/10.24292/01.MF.0417.6
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Tykarski A., Widecka K., Filipiak K.J.: Zasady postępowania w nadciśnieniu tętniczym – 2015 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Próba komentarza na temat zmian i ich zasadności. Nadciśn. Tętn. w Prakt. 2015; 2: 71-96.
2. Rutz-Danielczak A., Tykarski A.: Ramipril. Biblioteka Czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009.
3. Tykarski A., Kostka-Jeziorny K., Kawecka-Jaszcz K.: Chronoterapia nadciśnienia tętniczego. Arterial Hypertension 2006; 10(3): 235-250.
4. Erman A., Winkler J., Chen-Gal B. et al.: Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. Hypertens. 1991; 9: 1057-1062.
5. Piepho R.W.: Overview of the angiotensin-converting-enzyme inhibitors. Am. J. Health-Syst. Pharm. 2000; 57(supl. 1): S3-S7.
6. Kaplan N.M.: The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin. Ther. 1996; 18(4): 658-670.
7. Scheen A.J.: DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease. Rev. Med. Liege. 2006; 61(10): 728-732.
8. Widecka K., Szymański F.M., Filipiak K.J. et al.: Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arterial Hypertension 2017; 21(1): 1-9.
9. Lièvre M., Guéret P., Gayet C. et al.: Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril). Arch. Mal. Coeur. Vaiss. 1995; 88(2): 35-42.
10. MacMahon S., Sharpe N., Gamble G. et al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J. Am. Coll. Cardiol. 2000; 36(2): 438-443.
11. Agabiti-Rosei E., Ambrosioni E., Dal Palù C.: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J. Hypertens. 1995; 13(11): 1325-1334.
12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
13. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
14. Shahin Y., Cockcroft J.R., Chetter I.C.: Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br. J. Surg. 2013; 100(9): 1154-1163.
15. Bull S., Loudon M., Francis J.M. et al.: A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur. Heart J. Cardiovasc. Imaging. 2015; 16(8): 834-841.
16. Bang C.N., Greve A.M., Køber L. et al.: Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int. J. Cardiol. 2014; 175(3): 492-498.
17. Bosch J., Lonn E., Pogue J. et al.; on behalf of HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
18. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875): 821-828.
19. Borghi C., Cosentino E.R., Rinaldi E.R. et al.: Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am. J. Cardiol. 2013; 112(1): 90-93.
20. Grobbee D.E., Bots M.L.: Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 1994; 236: 567-573.
21. Mason R.P.: Cytoprotective properties of a long-acting calcium channel blocker: new mechanism of action. Am. J. Hypertens. 1998; 11: 245A-249A.
22. Zhang X., Hintze T.H.: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-580.
23. Wydra M., Kuch M.: Amlodypina – state of art. Medycyna Faktów 2013; 2(19): 7-14.
24. Neaton J.D., Grimm R.H., Prineas R.J. et al.: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713-724.
25. Pitt B., Byington R.P., Furberg C.D. et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 26: 1503-1510.
26. Nissen S.E., Tuzcu E.M., Libby P. et al.; for the CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2226.
27. Jorgensen B., Simonsen S., Endresen K. et al.: Restenosis and clinical outcomes in patients treated with amlodipine after angioplasty: results from Coronary AngioPlasty Amlodipine REstenosis Study (CAPARES). J. Am. Coll. Cardiol. 2000; 35: 592-599.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
29. Dahlof B., Sever P.S., Poulter N.R. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
30. Williams B., Lacy P.S., Thom S.M. et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
31. Julius S., Kjeldsen S.E., Brunner H. et al.: VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. 2003; 16(7): 544-548.
32. Jamerson K., Weber M.A., Bakris G.L. et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
33. Reichek N., Devereux R.B, Rocha R.A. et al.: Magnetic Resonance Imaging Left Ventricular Mass Reduction With Fixed-Dose Angiotensin-Converting Enzyme Inhibitor-Based Regimens in Patients With High-Risk Hypertension. Hypertension 2009; 54: 731-737.
34. Miranda R.D., Mion D. Jr, Rocha J.C. et al.: An 18-Week, Prospective, Randomized, Double-Blind, Multicenter Study of Amlodipine/Ramipril Combination Versus Amlodipine Monotherapy in the Treatment of Hypertension: The Assessment of Combination Therapy of Amlodipine/ Ramipril (ATAR) Study. Clin. Ther. 2008; 30: 1618-1628.
35. Tomcsányi J.: Monitoring of the blood pressure lowering effectiveness of ramipril-amlodipine fix combination – A non-interventional trial (RAMONA study) (Hungarian). Hypertonia es Nephrologia. 2013; 17: 34-38.
36. Simonyi G.: Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial. Chin. Med. J. (Engl). 2016; 129(10): 1224-1228.
37. Simonyi G., Ferenci T.: [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient’s adherence]. Orv. Hetil. 2016; 157(1): 30-34.
2. Rutz-Danielczak A., Tykarski A.: Ramipril. Biblioteka Czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009.
3. Tykarski A., Kostka-Jeziorny K., Kawecka-Jaszcz K.: Chronoterapia nadciśnienia tętniczego. Arterial Hypertension 2006; 10(3): 235-250.
4. Erman A., Winkler J., Chen-Gal B. et al.: Inhibition of angiotensin converting enzyme by ramipril in serum and tissue of man. Hypertens. 1991; 9: 1057-1062.
5. Piepho R.W.: Overview of the angiotensin-converting-enzyme inhibitors. Am. J. Health-Syst. Pharm. 2000; 57(supl. 1): S3-S7.
6. Kaplan N.M.: The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators. Clin. Ther. 1996; 18(4): 658-670.
7. Scheen A.J.: DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease. Rev. Med. Liege. 2006; 61(10): 728-732.
8. Widecka K., Szymański F.M., Filipiak K.J. et al.: Stanowisko ekspertów dotyczące hiperurykemii i jej leczenia u pacjentów z wysokim ryzykiem sercowo-naczyniowym. Arterial Hypertension 2017; 21(1): 1-9.
9. Lièvre M., Guéret P., Gayet C. et al.: Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril). Arch. Mal. Coeur. Vaiss. 1995; 88(2): 35-42.
10. MacMahon S., Sharpe N., Gamble G. et al.: Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J. Am. Coll. Cardiol. 2000; 36(2): 438-443.
11. Agabiti-Rosei E., Ambrosioni E., Dal Palù C.: ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group. J. Hypertens. 1995; 13(11): 1325-1334.
12. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000; 355(9200): 253-259.
13. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia): Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997; 349: 1857-1863.
14. Shahin Y., Cockcroft J.R., Chetter I.C.: Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication. Br. J. Surg. 2013; 100(9): 1154-1163.
15. Bull S., Loudon M., Francis J.M. et al.: A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial). Eur. Heart J. Cardiovasc. Imaging. 2015; 16(8): 834-841.
16. Bang C.N., Greve A.M., Køber L. et al.: Renin-angiotensin system inhibition is not associated with increased sudden cardiac death, cardiovascular mortality or all-cause mortality in patients with aortic stenosis. Int. J. Cardiol. 2014; 175(3): 492-498.
17. Bosch J., Lonn E., Pogue J. et al.; on behalf of HOPE/HOPE-TOO Study Investigators: Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112(9): 1339-1346.
18. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet. 1993; 342(8875): 821-828.
19. Borghi C., Cosentino E.R., Rinaldi E.R. et al.: Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure. Am. J. Cardiol. 2013; 112(1): 90-93.
20. Grobbee D.E., Bots M.L.: Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J. Intern. Med. 1994; 236: 567-573.
21. Mason R.P.: Cytoprotective properties of a long-acting calcium channel blocker: new mechanism of action. Am. J. Hypertens. 1998; 11: 245A-249A.
22. Zhang X., Hintze T.H.: Amlodipine releases nitric oxide from canine coronary microvessels: an unexpected mechanism of action of a calcium channel-blocking agent. Circulation 1998; 97: 576-580.
23. Wydra M., Kuch M.: Amlodypina – state of art. Medycyna Faktów 2013; 2(19): 7-14.
24. Neaton J.D., Grimm R.H., Prineas R.J. et al.: Treatment of Mild Hypertension Study. Final results. Treatment of Mild Hypertension Study Research Group. JAMA 1993; 270: 713-724.
25. Pitt B., Byington R.P., Furberg C.D. et al.: Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 26: 1503-1510.
26. Nissen S.E., Tuzcu E.M., Libby P. et al.; for the CAMELOT Investigators: Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: The CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217-2226.
27. Jorgensen B., Simonsen S., Endresen K. et al.: Restenosis and clinical outcomes in patients treated with amlodipine after angioplasty: results from Coronary AngioPlasty Amlodipine REstenosis Study (CAPARES). J. Am. Coll. Cardiol. 2000; 35: 592-599.
28. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group: Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981-2997.
29. Dahlof B., Sever P.S., Poulter N.R. et al.: Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366(9489): 895-906.
30. Williams B., Lacy P.S., Thom S.M. et al.: Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006; 113: 1213-1225.
31. Julius S., Kjeldsen S.E., Brunner H. et al.: VALUE trial: long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens. 2003; 16(7): 544-548.
32. Jamerson K., Weber M.A., Bakris G.L. et al.; ACCOMPLISH Trial Investigators: Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N. Engl. J. Med. 2008; 359: 2417-2428.
33. Reichek N., Devereux R.B, Rocha R.A. et al.: Magnetic Resonance Imaging Left Ventricular Mass Reduction With Fixed-Dose Angiotensin-Converting Enzyme Inhibitor-Based Regimens in Patients With High-Risk Hypertension. Hypertension 2009; 54: 731-737.
34. Miranda R.D., Mion D. Jr, Rocha J.C. et al.: An 18-Week, Prospective, Randomized, Double-Blind, Multicenter Study of Amlodipine/Ramipril Combination Versus Amlodipine Monotherapy in the Treatment of Hypertension: The Assessment of Combination Therapy of Amlodipine/ Ramipril (ATAR) Study. Clin. Ther. 2008; 30: 1618-1628.
35. Tomcsányi J.: Monitoring of the blood pressure lowering effectiveness of ramipril-amlodipine fix combination – A non-interventional trial (RAMONA study) (Hungarian). Hypertonia es Nephrologia. 2013; 17: 34-38.
36. Simonyi G.: Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial. Chin. Med. J. (Engl). 2016; 129(10): 1224-1228.
37. Simonyi G., Ferenci T.: [Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient’s adherence]. Orv. Hetil. 2016; 157(1): 30-34.